Company: CERO
Filing Date: 2025-04-25
Form Type: PRE 14A
Source: 0001213900-25-035562
Chunk: 120

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-04-25
Form: PRE 14A
Chunk 120
---
 occurs while the Pre -FundedWarrants are outstanding (which includes, but is not limited to, merger transactions or a sale of substantially all of the company’s assets), then if holders of the Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction (as defined in the Pre -FundedWarrant), then the holder will be given the same choice as to the consideration it receives upon any exercise of either the Pre -FundedWarrants following such Fundamental Transaction. Right as a Stockholder:Except as otherwise provided in the Pre -FundedWarrants or by virtue of such holder’s ownership of shares of our Common Stock, the holders of the Pre -FundedWarrants do not have the rights or privileges of holders of our Common Stock, including any voting rights, until they exercise their Pre -FundedWarrants. (B) February 2025 Common Warrants The following summary of certain terms and provisions of the February 2025 Common Warrants that are is not complete and is subject to, and qualified in its entirety by, the provisions of the February 2025 Common Warrant, the form of which is filed as Exhibit 4.7 to the registration statement filed with the SEC on February 5, 2025. Prospective investors should carefully review the terms and provisions of the form of February 2025 Common Warrant for a complete description of the terms and conditions of the February 2025 Common Warrants. 66 We issued and sold 2,551,020 February 2025 Common Warrants to purchase an aggregate of 2,551,020shares of our Common Stock. Each February 2025 Common Warrant has an exercise price per share of $1.96 and will be immediately exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the February 2025 Common Warrants (the “Warrant Stockholder Approval”) which we are seeking to obtain at our 2025 Annual Meeting of Stockholders. The February 2025 Common Warrants will expire on the 5 -yearanniversary of the Warrant Stockholder Approval. The February 2025 Common Warrants will be exercisable in whole or in part by delivering to the Company a completed instruction form for exercise and complying with the requirements for exercise set forth in the February 2025 Common Warrant. Payment of the exercise price may be made in cash, in which case the holder would receive upon such exercise the net